Management of lower urinary tract symptoms in Parkinson's disease in the neurology clinic

References

• Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007;27(5):494–506.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79(4):368–76 https://www.ncbi.nlm.nih.gov/pubmed/18344392
   PubMed Web of Science ®Google Scholar
• Park A, Stacy M. Non-motor symptoms in Parkinson's disease. J Neurol 2009;256:293–298.
   PubMed Web of Science ®Google Scholar
• Wolfgang HJ. Urological problems in Parkinson's disease: clinical aspects. J Neural Transm 2013;120:587–91.
   PubMed Web of Science ®Google Scholar
• Micieli G, Tosi P, Marcheselli S, Cavallini A. Autonomic dysfunction in Parkinson's disease. Neurol Sci 2003 May;24(Suppl 1):S32–4.
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Uchiyama T, Yamanishi T, et al. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm 2008;115:443–60.
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 2001;92:76–85.
   PubMed Web of Science ®Google Scholar
• Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 2000;68:429–33.
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Fuyuki T, Takeki N, et al. Bladder function of patients with PD. Int J Urol 2014;21:638–46.
   PubMed Web of Science ®Google Scholar
• Lemack GE, Dewey RB, Roehrborn CG, et al. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology 2000;56:250–54.
   PubMed Web of Science ®Google Scholar
• Campos-Sousa RN, Quagliato E, da Silva BB, Jr, et al. Urinary symptoms in Parkinson's disease: prevalence and associated factors. Arq Neuropsiquiatr 2003;61:359–63.
   PubMed Web of Science ®Google Scholar
• Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol 2000;164:1640–43.
   PubMed Web of Science ®Google Scholar
• McCrowther CW, Jagger C, Clarke M, et al. Handicaps associated with incontinence: implications for management. J Epidemiol Commun Health 1990;44:246–48.
   PubMed Web of Science ®Google Scholar
• Golabek T, Skalski M, Przydacz M, et al. Lower urinary tract symptoms, nocturia and overactive bladder in patients with depression and anxiety. Psychiatr Pol 2016;50(2):417–30.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Mougey J, Lambert L, et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int 2009;104(1):63–8.
   PubMed Web of Science ®Google Scholar
• de Groat WC, Griffiths D, Yoshimura N. Neural control of the lower urinary tract. Compr Physiol 2015;5(1):327.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Ogawa T, Miyazato M, et al. Neural mechanisms underlying lower urinary tract dysfunction. Korean J Urol 2014;55(2):81–90.
   PubMedGoogle Scholar
• de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Brit J Pharmacol 2006;147:S25–40.
   PubMed Web of Science ®Google Scholar
• Michel MC, Vrydag W. α1-, α2- and β-adrenoceptors in the urinary bladder, urethra and prostate. Brit J Pharmacol 2006;147(Suppl 2):S88–119.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004;84:935–86.
   PubMed Web of Science ®Google Scholar
• Naoki Y, Kaiho Y, Miyazato M, et al. Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn-Schmiedeberg's Arch Pharmacol 2008;377(4):437–48.
   Google Scholar
• Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453–66.
   PubMed Web of Science ®Google Scholar
• De Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Ann Rev Pharmacol Toxicol 2001;41:691–721.
   PubMed Web of Science ®Google Scholar
• Kavia RBC, Dasgupta R, Fowler CJ. Functional imaging and the central control of the bladder. J Comp Neurol 2005;493:27–32.
   PubMed Web of Science ®Google Scholar
• Matsumoto G, Hisamitsu T, De Groat WC. Role of glutamate and NMDA receptors in the descending limb of the spinobulbospinal micturition reflex pathway of the rat. Neurosci Lett 1995;183:58–61.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sakakibara R, Nakazawa K, et al. Micturition-related neuronal firing in the periaqueductal gray area in cats. Neuroscience 2004;126:1075–82.
   PubMed Web of Science ®Google Scholar
• Fowler CJ. Integrated control of lower urinary tract: clinical perspective. Brit J Pharmacol 2006;147:S14–24.
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Tateno F, Kishi M, et al. Pathophysiology of bladder dysfunction in Parkinson's disease. Neurobiol Dis 2012;46(3):565–71. doi:10.1016/j.nbd.2011.10.002.
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Nakazawa K, Uchiyama T, et al. Effects of subthalamic nucleus stimulation on the micturition reflex in cats. Neuroscience 2003;120:871–875.
   PubMed Web of Science ®Google Scholar
• Stone E, Coote JH, Allard J, Lovick TA. GABAergic control of micturition within the periaqueductal grey matter of the male rat. J Physiol 2011;589(8):2065–78.
   PubMed Web of Science ®Google Scholar
• Uchiyama T, Sakakibara R, Hattori T, et al. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 2003;18:573–78.
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–178.
   PubMed Web of Science ®Google Scholar
• Winge K, Nielsen KK. Bladder dysfunction in advanced Parkinson's disease. Neurourol Urodyn 2012;31(8):1279–83.
   PubMed Web of Science ®Google Scholar
• Lipp A, Sandroni P, Ahlskog JE, et al. Prospective differentiation of multiple system atrophy from Parkinson's disease, with and without autonomic failure. Arch Neurol 2009;66(6):742–50.
   PubMedGoogle Scholar
• Lepor H. Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol 2005;7(Suppl 4):S3–12.
   Google Scholar
• Deville WL, Yzermans JC, van Duijn NP, et al. The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. BMC Urol 2004;4:4.
   PubMedGoogle Scholar
• Fitzgerald MP, Graziano S. Anatomical and functional changes of the lower urinary tract during pregnancy. Urol Clin N Am 2007;34(1):7–12.
   PubMed Web of Science ®Google Scholar
• Rosseland LA, Stubhaug A & Breivik H. Detecting postoperative urinary retention with an ultrasound scanner. Acta Anaesthesiol Scand 2002;46(3):279–82.
   PubMed Web of Science ®Google Scholar
• Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract 2009;63(8):1177–91.
   PubMed Web of Science ®Google Scholar
• Johnson ST. From incontinence to confidence. Am J Nurs 2000;100(2):69–74.
   PubMed Web of Science ®Google Scholar
• MacDiarmid SA. Maximizing the treatment of overactive bladder in the elderly. Rev Urol 2008;10(1):6–13.
   PubMedGoogle Scholar
• Lohsiriwat S, Hirunsai M, Chaiyaprasithi B. Effect of caffeine on bladder function in patients with overactive bladder symptoms. Urol Ann 2011;3(1):14–8.
   PubMedGoogle Scholar
• Vaughan CP, Juncos JL, Burgio KL, et al. Behavioral therapy to treat urinary incontinence in Parkinson disease. Neurology 2011;76(19):1631–34.
   PubMed Web of Science ®Google Scholar
• Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2004;(1):CD001308.
   PubMedGoogle Scholar
• Marques A, Stothers L, Macnab, A. The status of pelvic floor muscle training for women. Can Urol Assoc J 2010 Dec;4(6):419–24.
   PubMed Web of Science ®Google Scholar
• Fader M, Cottenden AM, Getliffe K. Absorbent products for moderate heavy urinary and/or faecal incontinence in women and men. Cochrane Database Syst Rev 2008;(4):CD007408.
   PubMed Web of Science ®Google Scholar
• Canning CG, Paul SS, Nieuwboer, A. Prevention of falls in Parkinson's disease: a review of fall risk factors and the role of physical interventions. Neurodegener Dis Manag 2014;4(3):203–21.
   PubMedGoogle Scholar
• Aranda B, Cramer P. Effect of apomorphine and l-dopa on the parkinsonian bladder. Neurourol Urodyn 1993;12:203–09.
   PubMed Web of Science ®Google Scholar
• Donnellan C, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997;315:1363–64.
   PubMed Web of Science ®Google Scholar
• Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993;3(4):335–48.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Pavy-Le Traon A, et al. Emerging drugs for autonomic dysfunction in Parkinson's disease. Expert Opin Emerg Drugs 2013;18:39–53.
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Ogata T, Uchiyama T, et al. How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geriatr Soc 2009;57:1515–17.
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63(2):283–95.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388–95.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β (3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296–305.
   PubMed Web of Science ®Google Scholar
• Bhide AA, Digesu GA, Fernando R, Khullar V. Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder. Res Rep Urol 2012;4:41–5.
   PubMedGoogle Scholar
• Jiang YH, Liao CH, Tang DL, Kuo HC. Efficacy and safety of intravesical onabotulinumtoxin A injection on elderly patients with chronic central nervous system lesions and overactive bladder. PLoS One. 2014; 22;9(8):e105989.
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Rossi A, Mearini E, et al. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 2009;182:1453–57.
   PubMed Web of Science ®Google Scholar
• Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease. Parkinsonism Relat Disord 2010;16:531–4.
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Conte A, Proietti S, et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol. 2011 Sep;186(3):960–4.
   PubMed Web of Science ®Google Scholar
• Anderson RU, Orenberg EK, Glowe P. Onabotulinumtoxin A office treatment for neurogenic bladder incontinence in Parkinson's disease. Urology 2014;83:22–7.
   PubMed Web of Science ®Google Scholar
• Ohannessian A, Kaboré FA, Agostini A, et al. Transcutaneous tibial nerve stimulation in the overactive bladder syndrome in patients with Parkinson's syndromes. Prog Urol 2013;23(11):936–9.
   PubMed Web of Science ®Google Scholar
• Amit B, Natalie T, Mahreen P, Jalesh NP. Treatment options for urogenital dysfunction in Parkinson's disease. Curr Treat Options Neurol 2016;18:45.
   PubMed Web of Science ®Google Scholar
• Roth B, Studer E, Fowler C-J, et al. Benign prostatic obstruction and Parkinson's disease – should transurethral resection of the prostate be avoided? J Urol 2009;181(5):2209–13.
   PubMed Web of Science ®Google Scholar
• Ashkan K, Samuel M, Reddy P, Ray Chaudhuri K. The impact of deep brain stimulation on the nonmotor symptoms of Parkinson's disease. J Neural Transm (Vienna) 2013;120(4):639–42.
   PubMed Web of Science ®Google Scholar
• Seif C, Herzog J, Van Der Horst C, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 2004;55(1):118–20.
   PubMed Web of Science ®Google Scholar
• Herzog J, Weiss PH, Assmus A, et al. Improved sensory gating of urinary bladder afferents in Parkinson's disease following subthalamic stimulation. Brain 2008;131(1):132–45.
   PubMed Web of Science ®Google Scholar
• Herzog J, Weiss PH, Assmus A, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson's disease. Brain 2006;129:3366–75.
   PubMed Web of Science ®Google Scholar
• Finazzi-Agro E, Peppe A, D'Amico A, et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson's disease. J Urol 2003;169:1388–91.
   PubMed Web of Science ®Google Scholar
• Mock S, Osborn DJ, Brown ET, et al. The impact of pallidal and subthalamic deep brain stimulation on urologic function in Parkinson's disease. Neuromodulation 2016;19:717–23.
   PubMed Web of Science ®Google Scholar
• Hwynn N, Ul Haq I, Malaty IA, et al. Effect of deep brain stimulation on Parkinson's nonmotor symptoms following unilateral DBS: a pilot study. Parkinson's Dis 2011 Dec 19;2011:4. doi:10.4061/2011/507416.
   Web of Science ®Google Scholar
• Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014;29:1583–90. doi:10.1002/mds.25945.
   PubMed Web of Science ®Google Scholar
• Gomes, CM, Sammour ZM, de Bessa J Jr., et al. Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson's disease. Clinics 2014;69(12):817–22. http://doi.org/10.6061/clinics/2014(12)05.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Fujino T, Maruyama S, et al. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder. J Pharmacol Sci 2010;112(2):142–50.
   PubMed Web of Science ®Google Scholar
• Tamimi NAM, Mincik I, Haughie S, et al. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int 2010;106(5):674–80. doi:10.1111/j.1464-410X.2010.09204.x
   PubMed Web of Science ®Google Scholar
• Giuliano F, Lamb J, Crossland A, et al. A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. BJU Int 2010;106(5): 666–73.
   PubMed Web of Science ®Google Scholar
• Liu L, Zheng S, Han P, Wei Q. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology 2011;77(1):123–9.
   PubMed Web of Science ®Google Scholar
• Lombardi G, Nelli F, Celso M, et al. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors: review of the literature. J Sex Med 2012;9(4):970–85. doi:10.1111/j.1743-6109.2011.02615.x
   PubMed Web of Science ®Google Scholar
• Cialis (tadalafil) label FDA [Internet] [cited 17 Apr 2017]. Available from:http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf.
   Google Scholar
• American Urological Association. 2010. Guideline: management of benign prostatic hyperplasia [ cited 17 Apr 2017]. Available from: https://www.auanet.org/common/pdf/education/clinical-guidance/Benign-Prostatic-Hyperplasia.pdf.
   Google Scholar
• Füllhase C, Soler R, Gratzke C. New strategies in treating male lower urinary tract symptoms. Curr Opin Urol 2014;24(1):29–35.
   PubMed Web of Science ®Google Scholar
• Heranval A, Lefaucheur R, Fetter D, et al. Drugs with potential cardiac adverse effects: retrospective study in a large cohort of parkinsonian patients. Rev Neurol (Paris) 2016 Apr–May;172(4–5):318–23. doi:10.1016/j.neurol.2015.11.007.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang F, ZiXhian Y, et al . Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized, double-blind, placebo-controlled trial. Urology 2016;100:59–64. https://doi.org/10.1016/j.urology.2016.11.008
   PubMed Web of Science ®Google Scholar
• Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol 1988;140:117.
   PubMed Web of Science ®Google Scholar
• Fowler CJ. Neurological disorders of micturition and their treatment. Brain 1999;122:1213
   PubMed Web of Science ®Google Scholar
• Wyndaele JJ, Castro D, Madersbacher H, et al. Neurogenic and faecal incontinence. In: Abrams P, Cardozo L, Khouryand S, Wein A, eds. Incontinence. Vol. 2. Paris: Health Publications Ltd; 2005: 1059–162.
   Google Scholar